DendriMed, a spin-out from the University of Queensland, is developing a drug delivery platform that combines polymer and dendrimer nanotechnologies. The company is aiming to improve the delivery of a new class of drugs known as interfering RNA (RNAi) when applied to cancer treatment.
DendriMed Frequently Asked Questions (FAQ)
When was DendriMed founded?
DendriMed was founded in 2007.
Where is DendriMed's headquarters?
DendriMed's headquarters is located at Brisbane.
What is DendriMed's latest funding round?
DendriMed's latest funding round is Spinoff / Spinout.
Who are the investors of DendriMed?
Investors of DendriMed include University of Queensland and UniSeed.
Who are DendriMed's competitors?
Competitors of DendriMed include Brainsgate, Vapore, Ekos, Orthocon, Taiwan Liposome Company and 7 more.
Compare DendriMed to Competitors
Critical Pharmaceuticals is an advanced drug delivery company with core expertise in delivery of macromolecules such as DNA, proteins, peptides, siRNA and aptamers.
Selective Amplifier Genes offers artificial genes that improve the functions of vectors for use in blood disorders
Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.
Making the pain of injections go away in children, adults and seniors, is Israel's Sindolor. Based in Ramat Gan, under the TASE-traded mother company D Medical Industries, Sindolor is about to release its EZject drug delivery platform.
Berkeley Advanced Biomaterials Inc. (BAB) specializes in developing and manufacturing hydroxyapatite (HAP), tricalcium phosphate (TCP), and other calcium-based products. The company's activities are focussed on synthetic bone graft substitutes, sustained-release drug delivery devices, and applications of HAP for protein purification. The company's catalog offers a large variety of products with tailored morphologies and microstructures to match their needs for orthopedic surgery, bone tissue engineering, and life science research. Cem-Ostetic and Bi-Ostetic bone void fillers are approved for sale in the USA and the European Community.
Iaculor Injection Inc. develops low cost, more efficient needle-free injection devices that allow the delivery of powder or liquid forms of vaccines, small molecules and biologicals.